SCHEMBL23510596

SCHEMBL23510596

CCSC1=N/C(=C\c2ccc3scnc3c2)C(=O)N1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.59
▸ DYRK1A Q13627 16/20 0.57
▸ DYRK2 Q92630 13/20 0.57
▸ DYRK1B Q9Y463 13/20 0.57
▸ DYRK3 O43781 12/20 0.57
▸ CSNK2A2 P19784 4/20 0.57
▸ CSNK2B P67870 4/20 0.57
▸ CSNK2A1 P68400 4/20 0.57
▸ PIM1 P11309 3/20 0.57
▸ CSNK2A3 Q8NEV1 3/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ CLK4 Q9HAZ1 13/20 0.49
▸ CLK1 P49759 12/20 0.49
▸ CLK2 P49760 11/20 0.49
▸ CLK3 P49761 7/20 0.49
▸ DYRK4 Q9NR20 6/20 0.49
▸ GSK3B P49841 4/20 0.49
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23510493 0.91 CLK1 (0.60) KDM4EDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL30145002 0.91 CLK1 (0.60) KDM4EDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL28842886 0.91 CLK1 (0.60) KDM4EDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL24904263 0.81 KDM4E (0.64) KDM4EDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL30363461 0.81 KDM4E (0.64) KDM4EDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL30494246 0.79 KDM4E (0.60) KDM4EDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL26095300 0.79 KDM4E (0.60) KDM4EDYRK1ADYRK2DYRK1BDYRK3
SCHEMBL23970084 0.78 CLK1 (0.60) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL30144962 0.78 CLK1 (0.60) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL28945547 0.77 KDM4E (0.58) KDM4EDYRK1ADYRK2DYRK1BDYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TONGJI UNIVERSITY (CN) 2023-01-26 — — US disclosed
WO-2021115489-A1 NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES TONGJI UNIVERSITY (CN) 2021-06-17 — — WO disclosed
WO-2021114314-A1 NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES TONGJI UNIVERSITY (CN) 2021-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TNNI3, TNNT2, MKI67 KDM4E 3429/4885DYRK1A 3319/4885DYRK2 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback